H. Lundbeck A/S: New study presented at ECPN 2022 finds that vortioxetine improves depressive symptoms and cognitive function in patients with Major Depressive Disorder and co-morbid dementia

VALBY, Denmark, Oct. 18, 2022 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) announced positive data showing Trintellix/Brintellix (vortioxetine) significantly reduced depressive symptoms and improved

Related Keywords

Valby ,Hovedstaden ,Denmark ,Estonia ,Copenhagen ,Køavn ,Italy ,Austria ,Vienna ,Wien ,Poland ,France ,Spain ,Trintellix Brintellix ,Kristiney Nat ,Thomas Mikkel Mortensen ,Johan Luthman ,Lawrence Erlbaum Associates ,Alzheimer Disease International ,Linkedin ,Corporate Communications ,European College Of Neuropsychopharmacology ,Lundbeck ,Major Depressive Disorder ,European College ,Executive Vice President ,Depression Rating Scale ,Opin Psychiatry ,World Alzheimer Report ,Accessed September ,Gen Psychiatry ,Esp Psiquiatr ,Study ,Resented ,Acpn ,022 ,Kinds ,Vortioxetine ,Mproves ,Depressive ,Symptoms ,Cognitive ,Junction ,Patients ,Major ,Disorder ,Forbid ,Dementia ,